title: [Conventional therapeutic strategies for relapsed chronic lymphocytic leukemia].
abstract: The choice of salvage therapy for patients presenting relapsed chronic lymphocytic leukemia (CLL) has to take into account some factors influencing tumor resistance and comorbidities. Since 2010, new drugs targeting the tumor cells' signaling have been proposed for CLL patients. Waiting the results of various clinical trials evaluating these treatments, there is a need to describe the state-of-the-art concerning approved treatments such as chemotherapy and monoclonal antibodies.
authors.affiliation: Inserm CIC-501, EA7283, CHU Estaing, université d'Auvergne, service d'hématologie clinique adultes et de thérapie cellulaire, 1, place Lucie-Aubrac, 63000 Clermont-Ferrand, France. rguieze@chu-clermontferrand.fr
authors.forename: Romain
authors.initials: R
authors.lastname: Guièze
authors.forename: Loïc
authors.initials: L
authors.lastname: Ysebaert
authors.forename: Sophie
authors.initials: S
authors.lastname: de Guibert
authors.forename: Nathalie
authors.initials: N
authors.lastname: Dhédin
authors.forename: Jacques-Oliver
authors.initials: JO
authors.lastname: Bay
authors.forename: Xavier
authors.initials: X
authors.lastname: Troussard
authors.forename: Olivier
authors.initials: O
authors.lastname: Tournilhac
mesh_terms: D000367:Age Factors; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008198:Lymph Nodes / Q000473:pathology; D016879:Salvage Therapy / Q000379:methods; D055502:Secondary Prevention; D012720:Severity of Illness Index; D019172:Transplantation Conditioning
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents